When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.
Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.
Dissolution-permeation testing is helping drug developers better predict how food affects oral drug absorption by measuring both drug solubilization and membrane permeation, reducing the risk of misleading results from dissolution data alone.
Drug combination screening is helping oncology developers identify synergistic drug pairs, connect response patterns to tumor biology, and support more predictive, biomarker-guided strategies for precision cancer treatment.
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
Richard Johnson, PhD, says better characterization of NCEs in the early stages of development and identifying solubility issues early offers the opportunity to address poor bioavailability using formulation techniques that deliver enhanced drug exposure – reducing risk, conserving resources, and increasing the chances of clinical success.
Ascendia Pharmaceutical Solutions is drug development teams’ fast, flexible, and first time right CDMO partner. It makes theImpossible Possible through a comprehensive suite of pre-formulation, formulation development, cGMP manufacturing, and ICH stability services for a variety of dosage forms and clinical trial materials (CTM), using proprietary enabling nanotechnologies. The company built its success on its customer-centric BEST philosophy (Brilliant technology, Excellent service, Superior quality, and Trust).
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director …
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
August 5 – Injection Devices
August 12 – Lyophilization Manufacturing
August 19 – Excipients
August 26 – Gene Therapy